·AIM:To evaluate the safety and efficacy of the exudative age-related macular degeneration(ARMD)treated with intravitreal injections of bevacizumab(avastin).·METHODS:Totally 22 patients(22 eyes)with exudative ARMD were treated with intravitreal injections of bevacizumab(1.25mg),and reinjected at 6-week intervals.The patients who had macular edema or leakage(according to the results of the examination on the 12th week)were given another injection.After 6-month-follow-up,the changes of the average visual acuity and central macular thickness(CMT)were analyzed through the results of the optical coherence tomography(OCT)(1st week,1st month,3rd month and 6th month after the operation)and fundus fluorescence angiography(FFA)(3rd month and 6th month after the operation).·RESULTS:After 6-month-follow-up,the average visual acuity was improved,the average CMT was reduced by 92.59μm,and both data were significant to the treatment efficacy,macular edema and leakage were disappeared or obviously alleviated through FFA.No other adverse effects were observed except four cases of subconjunctival hemorrhage.·CONCLUSION:Intravitreal injections of bevacizumab can improve the visual acuity of exudative ARMD patients and alleviate macular edema.Repeating injection can improve the efficacy and reduce the rate of recurrence.Long-term efficacy and safety of this treatment need to be evaluated with more cases and further follow-up.·